Cargando…
Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder
The osmotic release oral system (OROS) methylphenidate formulation is a prolonged-release medication for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults. We conducted a seven-week open-label extension of a double-blind study to assess the safety...
Autores principales: | Buitelaar, Jan K, Ramos-Quiroga, J Antoni, Casas, Miguel, Kooij, J J Sandra, Niemelä, Asko, Konofal, Eric, Dejonckheere, Joachim, Challis, Bradford H, Medori, Rossella |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747385/ https://www.ncbi.nlm.nih.gov/pubmed/19777067 |
Ejemplares similares
-
Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate
por: Buitelaar, J. K., et al.
Publicado: (2012) -
Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial
por: Kooij, J J Sandra, et al.
Publicado: (2013) -
The effect of methylphenidate-OROS(®) on the narrative ability of children with attention-deficit hyperactivity disorder
por: Rausch, Tessa L., et al.
Publicado: (2017) -
Individualizing the dosage of Methylphenidate in children with attention deficit hyperactivity disorder
por: Shirafkan, Hoda, et al.
Publicado: (2020) -
Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants
por: Buitelaar, Jan, et al.
Publicado: (2009)